<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240759</url>
  </required_header>
  <id_info>
    <org_study_id>1010N0921</org_study_id>
    <nct_id>NCT01240759</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of S-707106 co-administered
      with metformin in subjects with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the unmet clinical need for more safe and effective type 2 diabetes mellitus
      therapies, together with the nonclinical efficacy and safety profile of S-707106, Shionogi
      USA, Inc. is initiating studies to further assess the efficacy, clinical pharmacology and
      safety profile of S-707106 in preparation for full clinical development as a novel treatment
      for type 2 diabetes mellitus. It is anticipated that S-707106 will provide clinicians and
      patients with a new therapeutic option to treat type 2 diabetes mellitus with potential
      advantages over existing therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Week 12 in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
    <description>Hemoglobin A1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serial pharmacokinetic (PK) assessments</measure>
    <time_frame>5 days</time_frame>
    <description>Serial pharmacokinetic sampling at Visit 6 prior to dosing, at Visit 7 prior to dosing and at 0.5, 1, 2, 3, 4, 6, 8 and 24 hours after dosing, at Visit 8, at Visit 9, and Early Termination Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sparse pharmacokinetic assessments</measure>
    <time_frame>5 days</time_frame>
    <description>Sparse pharmacokinetic sampling at Visit 6 and Visit 7 prior to dosing, at Visit 6 or Visit 7 one additional post-dose sample, at Visit 8, at Visit 9, and Early Termination Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with Hemoglobin A1c &lt; 7.0% at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hemoglobin A1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at Week 12 in: Fasting plasma glucose, 1,5-Anhydroglucitol, Fructosamine, Glycoalbumin, C-peptide, Beta-cell function and insulin resistance indices using Homeostatic Model Assessment, and Postprandial glucose test</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
    <description>Fasting plasma glucose, 1,5-Anhydroglucitol, Fructosamine, Glycoalbumin, C-peptide, Beta-cell function and insulin resistance indices using Homeostatic Model Assessment, and Postprandial glucose test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments</measure>
    <time_frame>5-6 months</time_frame>
    <description>Safety will be assessed by monitoring of treatment-emergent adverse events, serious adverse events, treatment-emergent adverse events leading to study drug discontinuation, clinical laboratory evaluations, vital signs, 12-lead electrocardiograms (ECGs), adrenal axis hormones, and treatment-emergent adverse events of hypoglycemia, hyperglycemia, confirmed hypoglycemia or hyperglycemia</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>S-707106 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One S-707106 A tablet + 3 Placebo A tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-707106 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One S-707106 B tablet + 3 Placebo A tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-707106 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-707106 Dose C = Four S-707106 B tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The standard of care dose of metformin for the individual patient + 3 Placebo A tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-707106 Dose A</intervention_name>
    <description>One S-707106 A tablet</description>
    <arm_group_label>S-707106 Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-707106 Dose B</intervention_name>
    <description>One S-707106 B tablet</description>
    <arm_group_label>S-707106 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-707106 Dose C</intervention_name>
    <description>Four S-707106 4 X B tablets</description>
    <arm_group_label>S-707106 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo A tablet</intervention_name>
    <description>Up to 4 Placebo A tablets</description>
    <arm_group_label>S-707106 Dose A</arm_group_label>
    <arm_group_label>S-707106 Dose B</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>The standard of care dose of metformin for each patient</description>
    <arm_group_label>S-707106 Dose A</arm_group_label>
    <arm_group_label>S-707106 Dose B</arm_group_label>
    <arm_group_label>S-707106 Dose C</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Subjects with type 2 diabetes mellitus receiving a stable dose of metformin for the
             past 3 months (with no other medication for glycemic control) and who are clinically
             stable as determined by medical history

          -  Body mass index (BMI) ≥25.0 and &lt;45.0 (kg/m2) using http://www.bmicalculator.org/ as
             the BMI calculator

          -  No clinically significant abnormal laboratory tests as determined by the investigator
             except Hemoglobin A1c level ≥7.5% and ≤11.0% and C peptide level &gt;1.0 ng/mL

        Main Exclusion Criteria:

          -  Type 1 diabetes mellitus or gestational diabetes mellitus within last 6 months

          -  Use of any medication for glycemic control other than metformin during the past 3
             months or thiazolidinediones within the past year

          -  Congestive heart failure as defined by New York Heart Association class III or IV

          -  Fasting glucose &gt;270 mg/dL

          -  Creatinine clearance is &lt;60 mL/minute

          -  History of myocardial infarction within the past 3 months, history of clinically
             significant cardiac arrhythmia, clinically significant hypotension or hypertension, or
             clinically significant abnormal electrocardiogram as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juno Research, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <disposition_first_submitted>April 26, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 27, 2018</disposition_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

